PHOENIX, Feb. 16, 2023 /PRNewswire/ — 1606 Corp (OTC: CBDW), an acquisition-based CBD + Hemp retail product distribution company, announces that 1606 Corporation has entered into an Equity Financing Agreement and Registration Rights with GHS Investments LLC. Under the terms of the Equity Financing Agreement, GHS agreed to provide 1606 Corp with, up to $20,000,000, to be used for acquisition financing after the registration of an S-1 filed with the U.S. Securities and Exchange Commission.

1606 Corp is pleased with the terms of the deal disclosing that the purchase price of all equity by GHS shall be eighty percent (80%) of the market price. Following an up-list to the NASDAQ or an equivalent national exchange by the Registrant, the purchase price of equity related to this registration will be purchased at ninety percent (90%) of the market price, subject to a floor of $2.00 per share, below which the company shall not deliver any puts.

The use of funds for the $20,000,000 equity financing is earmarked to acquire and develop additional CBD brands, distribution networks, and businesses. By building the portfolio of CBD businesses through acquisitions, 1606 Corp aims to add shareholder value by utilizing this equity line of credit.

1606 Corp is committed to adding shareholder value and believes that this is a great step, along with funding for acquisitions, to do that.

“We’re moving fast. Now that we have our feet underneath us since receiving the ticker symbol CBDW and now we’re taking definitive steps toward adding shareholder value. This $20 Million-dollar financing is going to allow us to buy profitable CBD companies and we’ll be a great investment opportunity for investors around the world.” Said CEO and Chairman Greg Lambrecht 

About 1606 Corp;

1606 Corp acquires and develops CBD brands including Truz and CBD Singlez, (www.1606hemp.com). The company utilizes an acquisition model aimed at consolidating the fragmented CBD industry. 1606 Corp has a primary focus on Hemp and CBD products, brand development, and establishing distribution channels. 1606 Corp. was awarded the ticker symbol CBDW on January 12th, 2022 and began trading on the OTC Market on January 17th, 2023.

About the CBD Industry;

The Cannabidiol (CBD) market accounted for USD 12.8 billion in 2021 and is estimated to grow with a 21.7% CAGR between 2022 and 2028, according to Grand view research (link). The global cannabidiol (CBD) market size was valued at $5.18 billion in 2021 and is expected to expand, at a compounded annual growth rate (CAGR) of 16.8% from 2022 to 2030. Cannabidiol (CBD) is a chemical compound that is found in the cannabis Sativa plant, and is extracted from hemp or cannabis, generally from hemp due to its naturally high cannabidiol (CBD) content…

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief, or current expectations of 1606 Corp (the “Company”), its directors, or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the Company’s control and which could, and likely will materially affect actual results, levels of activity, performance, or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Contact:
Greg Lambrecht
greg@1606corp.com
CBD.inc

Austen Lambrecht
austen@1606corp.com
CBD.inc

888-223-9510

Company Websites;
www.1606hemp.com
www.CBD.Inc

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

OKLAHOMA CITY (PRWEB) JANUARY 26, 2023

The launch of the Chronic Magazine’s new app has caused an uproar among weed tech companies. The new “Chronic Magazine: Weed Near Me” app provides cannabis resources and news with interactive maps and social groups to challenge cannabis censorship and provide a safe space for discussion.

Users can explore cannabis-related events on the maps as well as see dispensary listings, get the latest updates on legalization initiatives, and have access to products and services that are just a swipe away.

The developers behind the app believe that it will become an essential tool for cannabis users, activists, businesses, and professionals combating the stigma and educating about the plant’s medicinal uses.

However, some weed tech companies have denounced the app’s launch as competition for their own products, which could mean fewer profits for them in the future. This has created quite a controversy within the industry.

With more states legalizing medical and recreational cannabis, many entrepreneurs are trying their hand in this growing industry. But one company is standing out among the rest The Chronic Magazine, They are the fastest-growing cannabis magazine in the U.S. They started in the booming marijuana market in Oklahoma and now has branched out to readers all over the US, Canada, Australia, and Europe.

The Chronic Magazine has just announced the launch of its new Cannabis News APP. This APP will have everything from up-to-date cannabis news, strain information, cannabinoid profiles, CBD & Terpenes information, Psychedelics information, and cannabis recipes from world-renowned Chef Buz Deliere! As if that wasn’t enough, they have included Interactive Maps so you can find Dispensaries and marijuana-related events near you.

This app is different than any other weed tech company because it offers more than an interactive map that users can use to easily find dispensaries near them but also they can stay up-to-date on marijuana news with ease! It also has a social function called “Sesh Groups” where users can join and connect with like-minded people from around the world. They aim to stop cannabis censorship and allow people to converse freely around the plant. They do have a MOD team they have put in place to stop the spread of illegal activity and to ensure that anyone new to the use of marijuana can have resources that are trustworthy.

The Chronic Magazine App is set to revolutionize how people access cannabis-related information, while potentially causing disruption within the weed tech industry.

The App is available on both Apple and Android.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

$75,000 Pilot Lot Payment Received for Phase I of Safer Medical of Montana Agreement; Phases II/III Commercial Scale-Up Scheduled for Early 2023 – Expected to Yield 1^st Half 2023 Revenues Over $1 Million

SOUTH EASTON, MA / ACCESSWIRE / December 13, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide nutraceuticals, cosmetics, biotherapeutics, and food/beverage industries, among others, today confirmed the shipment of the Company’s first ever commercial production lot of a revolutionary nanoemulsion product created and enabled by the Company’s innovative Ultra Shear Technology (UST or UltraShear) nanoemulsification platform. The shipped product is a breakthrough CBD oral spray designed by PBI for fast effect and high potency for Safer Medical of Montana (“SMM”), with whom PBI signed a multi-year development and manufacturing agreement (“Agreement”), announced on May 4, 2022. SMM pre-paid the entire $75,000 purchase price of the Phase I production lot.

The Agreement covers three phases of development and commercialization of a custom-formulated oral spray of hemp-derived nanoemulsified CBD designed for extremely rapid absorption and effectiveness, and for efficient high potency delivery of CBD active material in each dose. All ingredients used in the manufacture of this UltraShear prepared nanoemulsion product are sourced from naturally-occurring, plant-based origins. Phases II and III of the PBI-SMM Agreement are focused on scaling up UltraShear nanoemulsion production by a factor of 10x in each stage, with total PBI revenues captured under this Agreement expected to top $1M in Q1/Q2 of 2023.

Captain George Ackerson, the CEO and Founder of Safer Medical of Montana, stated: “I am so excited by our opportunity to partner with Pressure BioSciences in allowing the launch of their first UltraShear-enabled nanoemulsion product to be focused upon creation of our revolutionary “Black Ops Nano CBD” oral spray, which is specifically targeted to serving vast unmet needs within the U.S. veterans community. Their UltraShear technology platform allows an oil-soluble active molecule like CBD to be prepared into a nanoemulsion of vanishingly tiny oil droplets in water that ensures rapid absorption and unparalleled bioavailability of the CBD into the water-based biochemistry of human bodies. Development work to date has demonstrated these capabilities far beyond any CBD products currently on the market – with performance better than we could have dreamed.”

Captain Ackerson continued: “As a Vietnam veteran myself, I wanted to make certain that our CBD product had the best chance of helping the men and women who have served our Country, many of whom still struggle daily with significant health and wellness issues. To ensure optimal effectiveness with fast validation in a positive first use experience, we requested the development of a very high concentration of CBD (40mg per milliliter), which is beyond the concentration capabilities of currently marketed true nano formulations. Each bottle contains 2000mg of CBD. One spray will deliver about 6.5mg of the nanoemulsified CBD, designed for fast absorption through the cheek or under the tongue. Individual users will be able to adjust their dosage easily and rapidly as needed.”

Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: “This launches a new chapter for Pressure BioSciences, as UltraShear commercialization enters into a phase of scale up and rapid growth. PBI has long established itself as an expert in the development and application of extreme high-pressure technology to enable remarkable and important new scientific and production capabilities, but UltraShear now opens an extraordinarily broad range of important and large new commercial application markets, from pharmaceuticals to nutraceuticals, cosmetics, food and beverages, agrochemicals, and many more.”

Mr. Hollister continued: “Black Ops Nano CBD is the first UltraShear product, but vastly more products, far beyond this initial cannabinoid opportunity, will quickly follow. We have previously announced exciting progress in our cosmeceutical partnership with Dr. Denese SkinScience, and in our formulation developments for astaxanthin (the most potent antioxidant in the market) and other nutraceuticals. Our investors should expect to hear much more about additional UltraShear contracts and products in the days and weeks ahead. The dam is bursting.”

Mr. Richard T. Schumacher, President and CEO of PBI, concluded: We recently announced the first three cosmeceutical products targeted for development and commercialization with Dr. Adrienne Denese through the initial quarters of 2023 PBIO/Dr. Denese FORCE Webinar 101322. Combined with the CBD product formulations already announced with orders from Captain Ackerman and other partners, we expect these UltraShear products to yield at least $4 million of incremental new toll manufacturing revenues for PBI through Q1/Q2 of 2023. We are also close to executing a number of additional UltraShear contracts that we anticipate will drive Q3/Q4 2023 tolling revenues well beyond the expected Q1/Q2 record revenues created by the UltraShear platform. This is a wonderful time to consider becoming or being a stakeholder in Pressure BioSciences.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

Press Contacts:
Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)
Jeffrey N. Peterson, Chairman (650) 703-8557(T)

SOURCE: Pressure BioSciences Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Cannabidiol, or CBD, and other cannabinoids are oil-based compounds. The human body is a water-based environment. To get the CBD where it needs to go, an emulsion of oil- and water-based ingredients has to be made. Emulsions can be achieved chemically or physically, and each approach has its downside. Most physical emulsions tend to separate over time (in minutes, days, even weeks) like the Italian dressing you vigorously shake before putting it on your salad. Many of the chemicals commonly used for emulsification are perhaps not the best things to put into your body.

In answer to this dilemma, one innovative laboratory equipment company has developed a revolutionary solution that provides very stable and clean nanoemulsions that can be used to effectively deliver oil-based ingredients into the water-based world of human and animal bodies. Pressure BioSciences, Inc. (OTCQB: PBIO) is currently offering its patented Ultra Shear Technology (UST) through an early access program, with the full product launch expected later this month. UST utilizes very high pressure (several times the pressure at the bottom of the Marianas Trench) to shear oil drops containing the active ingredients (nutraceuticals, vitamins, supplements, pharmaceuticals) to nano-sized droplets, enabling these important ingredients to be absorbed by the body far faster and more efficiently than previously practical or possible.

How Oil and Water Emulsions Are Made (CBD Oil Used as an Example)

PBIO’s UST platform is a bit of a mix of the two main approaches to emulsification – physical and chemical – with major improvements to both. Physically, the oil drops used to transport the active ingredient (e.g., CBD) are sheared down into much smaller individual droplets than most if not all currently available processes. The company is shearing CBD oil into droplets measured in nanometers. A nanometer is one-billionth of a meter, so small it’s really hard to comprehend. A sheet of paper is 100,000 nanometers thick. There are 25,400,000 nanometers in one inch. PBIO’s goal is to reduce the size of the UST-processed nano oil droplets (of which there could be billions) – regardless of the active ingredient contained in the oil – to under 100 nanometers each (smaller than bacteria).

The UST platform does this by using super-high pressure (in the neighborhood of 45,000 psi) to push the CBD oil and water mixture through its patented Nano Gap Valve. The combination of high pressure and the intense shear that happens as the mixture goes through the incredibly small valve opening shears the CBD oil/water emulsion to a microscopic level. The resulting nanodroplets of oil are so small (under 100 nanometers) they become a very long-term stable, “effectively water soluble”, and highly bioavailable nanoemulsion capable of extremely efficient delivery of CBD throughout the body. 

While most competitors make their nanoemulsions using chemicals with names that are difficult to pronounce, the patented UST process is so effective at shearing the CBD oil to nanodroplet sizes that PBIO can use very small amounts of all natural, plant-based additives in its formulations. This is a major improvement over the common practice of adding chemical emulsifiers like glycerol monostearate, silicone, sodium isethionate, polysorbate, and other substances to products that are supposed to be good for you. Many of these common emulsifiers are based on petrochemicals, some create toxic byproducts, and most are a far cry from ‘natural’ as most people understand the word.

In the images below, taken from PBIO’s investor presentation, you can see the clarity and stability achieved by using the UST platform when compared to a competitor’s conventionally processed emulsion. These conventional emulsions are almost never nanoemulsions, and the difference is startling.

Commercialization Underway

Pressure BioSciences has a long history in the laboratory instrument and equipment industry, and it has hundreds of instruments in many of the most respected labs around the world. These instruments use the company’s Pressure Cycling Technology (or PCT) platform, not UST. The primary areas of focus of these PCT instruments have been in drug discovery and development, biomarker discovery, and forensic science. The company’s PCT platform has been used for years in the development of new drugs, diagnostics, and treatment options for multiple important areas of human disease and disabilities, such as cancer and infectious diseases. 

PBIO’s experience in developing, selling, and servicing hundreds of PCT instruments worldwide offers confidence that the company has the ability to do the same for its new, about to be commercially launched, UST platform, the BaroShear K45 System. The BaroShear K45 is capable of producing many liters of nanoemulsified oil (CBD or other) per minute. Initial target markets include nutraceuticals (e.g., CBD), vitamins (e.g., D3), anti-oxidants (e.g., astaxanthin), supplements (e.g., curcumin) and cosmetics products (e.g., containing retinol).

PBIO is slated to open two fee-for-service, GMP-compliant tolling centers capable of handling larger volumes for contract partners. One center is scheduled to open later this month at the company’s headquarters in Massachusetts; the other will be opening in a few months in southern California. Because the BaroShear K45 is capable of more production than the initial benchtop small capacity systems used to prove the UST process, these new locations will be able to produce nanoemulsions on a much larger, commercial scale.

Due to increased customer demand ahead of the facility openings, the company created an Early Access Program in May 2022 designed to get the ball rolling with some early adopters. The idea has taken hold, and the company has announced three deals with CBD products companies. One is for an oral CBD spray, another for a topical CBD spray, and a third for nano-CBD bulk product that can be further formulated into other products on a white label basis. Each of these contracts is projected to create $1 million+ in 2023 revenue for PBIO, with more potential in the future depending on the success of the products. The company has also specifically been generating strong interest with cannabis drink manufacturers, a high growth area to keep an eye on.

Pressure BioSciences is expecting to announce more CBD/cannabis deals in the near term and is simultaneously addressing other industries as well. The company recently announced a major deal with Dr. Denese SkinScience, a pioneer in the anti-aging skincare industry that averages around $20 million/year in sales. It’s an initial two-year R&D deal, with some existing products anticipated to utilize UST processing while other products are under development. There are plenty of other target markets for the technology beyond cannabinoids and cosmetics as well, including food and beverage, inks and paints, agrochemicals, health and wellness, and pharmaceuticals.  Basically, if the active ingredient is in oil, PBIO believes it can nanoemulsify it, which would then significantly increase its stability, effective water solubility, and of course bioavailability.

For now, know that UST represents a true breakthrough technology, providing CBD and other cannabinoid products that offer superior quality, long-term stability, effective water solubility, and best-in-class bioavailability. Interested parties are encouraged to contact Pressure BioSciences directly to find out more about the technology’s capabilities and the company’s Early Access Program. Investors are encouraged to keep an eye on Pressure BioSciences (OTCQB: PBIO) as commercialization in several target markets proceeds and revenues hit the books.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

Cannabidiol, or CBD, has become one of the world’s most popular health and wellness supplements. According to the Brightfield Group, CBD sales could reach $16 billion in the U.S. alone. A growing body of evidence suggests that CBD could be beneficial in treating many health concerns, while upcoming FDA regulations could boost public confidence.

Sexual health and wellness represent a growing market where CBD products could prove beneficial. According to Arizton, the U.S. sexual wellness market could reach $9.34 billion by 2026, growing at an 8.27% compound annual growth rate. And many researchers believe that CBD could play a central role over the coming years.

How CBD Impacts Women’s Health

The human endocannabinoid system helps regulate everything from learning and memory to inflammatory and immune responses. So, not surprisingly, emerging research suggests that cannabinoids like CBD may influence sexual health and wellness through many mechanisms of action – including stress relief, inflammation reduction, and more.

While CBD is not psychoactive like its cousin THC, it boosts a neurotransmitter known as anandamide. Anandamide influences oxytocin, or the “cuddle hormone,” and helps increase endorphins and other neurotransmitters that improve mood. And ultimately, that can help women remain calm and focused on enjoyment.

The numerous cannabinoid receptors in reproductive organs and sexual tissues also mean that CBD may help increase blood flow to tissues. As a result, women could see greater sensitivity and promote the body’s natural lubrication. And these dynamics could help promote fewer painful experiences and more pleasurable experiences.

CBD could also have an impact on several related medical conditions, including:

• Vulvodynia
• Hemorrhoids
• Vaginismus
• Pelvic Floor Dysfunction
• Vaginal Scarring
• Candida & Fungal Infections
• Ovarian Cysts
• Vaginal Dryness

These markets could be worth billions of dollars per year and affect millions of women in the United States and around the world.

How to Invest in the Growing Niche

BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN), a newly public cannabis and software business based in Israel, recently signed a share purchase agreement to acquire the developers of EZ-G, a therapeutic device that uses low concentrations of CBD oils to treat certain women’s reproductive health issues and improve sexual health and wellness.

In particular, the unique, patent-pending device uses proprietary software to regulate the flow of low-concentration CBD oils into the soft tissues of the female reproductive system. According to research conducted across the globe, treatment with low-concentration CBD oils can relieve candida, dryness, scars, and many other female health issues.

The company intends to pursue the final registration of the patent and establish a marketing and sales system for the EZ-G device focused on both B2B and B2C channels. In the meantime, the company plans to start prototype production, validation tests, and contracts with suppliers to produce the device and the oils used.

Looking Ahead

CBD has the potential to transform women’s sexual health and wellness through both physiological and psychological mechanisms of action. While there is no shortage of CBD oils and other products, BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) is developing an innovative medical device and aims to secure FDA approval.

In addition to the EZ-G, BYND owns and operates a customer relationship management (CRM) solution – including a cannabis-specific CRM solution for medical marijuana growers. They’re also in the process of acquiring a cannabis license, enabling them to sell cannabis products in Israel, as well as export products to Germany and other European markets.

For more information, visit the company’s website.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

California’s legalization of recreational cannabis was an event in some ways reminiscent of the state’s famed Gold Rush 170 years earlier. There was gold in them thar hills and money in the air. Companies were lined up to secure licenses, and riches were sure to follow. Though the California cannabis industry has experienced some growing pains due to regulatory and black market pressures, it still represents the world’s largest legal cannabis market. One company, Moxie, can truly say they’ve been there from the beginning. 

In 2017 Moxie was awarded California’s first cannabis business license. Since its founding in 2015, the company has focused on premium quality, sustainable practices, and careful expansion. That approach has resulted in highly awarded brands, multi-state growth, and a palette of products far beyond the scope of its initial focus on extracts. 

Moxie’s Roots

In 2015 four friends decided to create and self-fund the highest quality cannabis concentrates available, a product they could all be proud of. All of them were already working in the medical cannabis industry, and have since brought on a broader team of professionals from other industries like consumer packaged goods, aerospace, and specialty pharmacy operations. The four friends/founders still work at Moxie today. Their combined passion for and commitment to the highest quality products made in the cleanest and most socially conscious way permeates the company’s culture. 

The results have been objectively outstanding to date. Jordan Lams was named one of the 100 most influential people in the cannabis industry by High Times. The brands, products, and company have won over 100 international awards to date. Moxie products are now distributed in 4 states, and the company owns and operates facilities in both Utah and California. The company’s focus on efficiency and state of the art technology means its 11,000 square foot manufacturing facility in California is capable of producing $120 million worth of products each year, and a 16,000 sf facility in Utah just recently opened.

Moxie prides itself on its diverse premium genetic portfolio with every strain founder-tested and approved. The company’s commitment to the highest quality at every step of the way from seed to sale is evidenced by the raft of awards and extensive distribution. Moxie has grown from the original focus on concentrate to a wide ranging offering across three brands and ten+ product categories.

What’s Next

Building on its proven product portfolio and multi-market distribution footprint, Moxie is eyeing further expansion. The company is looking at opportunities in key markets, including Nevada, Arizona, Michigan, New York, Maryland, Florida and Illinois. Expansion could happen as an owner/operator in these new markets, or as a result of strategic partnerships. In Pennsylvania, Moxie’s 2021 partnership resulted in a #4 ranking for the brand overall and a #1 ranking for its concentrates. The deal is valued over $100 million on Moxie’s side of the ledger. In Utah, Moxie went direct and won 1 out of only 14 retail dispensary licenses alongside its processing license.

Moxie has a track record of success, from its pioneering California days to international distribution and multi-state expansion in the US. Keep an eye out for further news from the company, as its brands may soon be available in a dispensary near you.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

Superfoods refer to nutrient-rich foods that convey positive health benefits. While catechin-rich green tea, fisetin-rich strawberries, and omega-3-rich walnuts are well-known superfoods, coca leaves remain relatively undiscovered due to their association with cocaine. But fortunately, decocainized coca leaves open the door to new possibilities.

Let’s take a deep dive into the nutritional benefits of coca leaves and how you can invest in one of the only companies bringing them to market.

What’s in Coca Leaves?

Coca leaves have been used for centuries as a natural herbal remedy for upset stomach, environmental stress, weight loss, and energy. In fact, indigenous cultures across South America still consume raw coca leaves regularly to achieve these health benefits. However, importing raw coca leaves into the U.S. is illegal due to their cocaine content.

Power Leaves Corp. plans to use state-of-the-art extraction technologies to decocainize coca leaves and bring premium extracts to the U.S. market. These extracts will provide the enormous potential health benefits of coca leaves to energy drinks, protein bars, and other convenient product formats for athletes and health-conscious individuals.

Coca leaves have four core benefits:

• High Protein – Coca leaf extract has 72% more protein than average plant-based foods, according to a Harvard analysis of protein requirements, with 19 grams of protein per 100 grams of extract. In other words, consumers can meet one-third of their protein intake requirements with just 100 grams of coca extract.
• Polyphenols – Coca leaf extract has three grams of polyphenols per 100 grams of extract, which is three times greater than what most consumers take in each day. In addition, unique processes could improve bioavailability compared to other sources, according to the company’s literature.
• Low GI Carbs – Coca leaf extract provides 44 grams of carbohydrates per 100 grams of extract but has a low glycemic index to maintain ideal blood sugar levels.
• High Calorie/ Fuel – Coca leaf extract provides over 300 calories per 100 grams, translating to 10% more calorie content than other plant-based foods. However, these calories stem mainly from protein and low-GI carbohydrates, making them “healthier” calories.

Coca leaves also provide other nutrients:

* Data from a company-provided nutritional analysis. Daily values from MyPlate.gov.

A Potential Game-Changer

The functional food and beverage market will grow from $258.8 billion in 2020 to nearly $530 billion by 2028, according to Fortune Business Insights, representing a 9.5% compound annual growth rate. Consumers are increasingly seeking nutrient-enhanced foods to improve their health while new product development is supercharging growth.

Coca could follow in the footsteps of hemp – another superfood held back by prohibition in the past. According to IMARC, the global hemp-based food market exceeded $1 billion in 2021 and could reach nearly $3 billion by 2025, representing a 15.52% compound annual growth rate. That’s about 50% faster than the broader functional food market.

Coca leaf extract is well-suited for the functional food and beverage industry, given its nutritional profile. In particular, it provides a high-protein, high-calorie, low-fat, and low-GI food source for the fitness community, along with antioxidants and essential micronutrients that may appeal to those seeking a healthier overall diet.

Investing in the Coca Market

Power Leaves Corp. is the first and only private commercial business to sign a government-approved 15-year exclusive license to extract, manufacture, and distribute decocainized coca-based products in the United States. The company achieved this status through its partnership with an indigenous group with a UN exemption.

The company plans to initially provide bulk extract to food and beverage customers across the U.S. Soon after, it plans to launch its organic and liquid biofertilizer products along with a coca-infused energy drink and tequila. These markets garner hundreds of billions of dollars in annual sales, translating to a significant opportunity for investors.

While it plans to list on the NASDAQ over the next nine to 12 months, investors can participate in a private placement of up to 22,222,222 units consisting of one common share and one-half share purchase warrants (for one common share at US$0.60 for 24 months). For more information, email [email protected] or sign up using the form below.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Hero Technologies Inc. (OTC: HENC) is focused on building a vertically integrated cannabis operation in Michigan that will expand to become a multi-state operation. The company is currently in the midst of the licensing process in Michigan. In anticipation of receiving the appropriate licenses, Hero has been laying the groundwork for construction of a large cultivation facility on a 120 acre site in Pulaski, Michigan.

The operation is based on cutting edge technologies aimed at maximizing crop yield and quality while minimizing cost and waste. Hero’s majority-owned subsidiary, Blackbox Systems and Technologies, is leading the effort in Michigan and the Blackbox aeroponic cultivation system lies at the heart of the company’s strategy.

CFN sat down with Blackbox CEO and Founder Marc Kasabasic to discuss the company’s technology, the sustainable and efficient design of the facility, and Hero’s strategy to start in Michigan and branch out from there.

• What is your background and what inspired you to create Blackbox?

My background is in Engineering and Architecture, specializing in large-scale structural infrastructure testing. I have a BSCE in Civil Engineering and a BSARCH in Architecture. I then got my MSCE in Structural Engineering at Lawrence Technological University (LTU) in Southfield MI. I am currently a research project engineer at LTU in the Center for Innovation Material Research (CIMR) specializing in large-scale testing. I am responsible for 22,000 square feet of high-tech testing facilities. I have a strong background in environmental and industrial control systems. I was a carpenter for years during high-school and college years, so not only do I like to test things, I like to build them as well.

Click here to learn more about investing in Hero Technologies

In 2010, Michigan opened up for medial cannabis and my partner Hank Pielack and I co-founded the Blackbox Project. We started this as a hobby, but quickly grew into a high-tech research project to solve some industry problems. We wanted a system that was the most precise delivery system for plants. This system needed to solve the structural component issue with aeroponic systems to allow large-growing plants to thrive in an artificial environment.

We recognized a number of industry problems, including excess waste, use of pesticides, and an excessive amount of labor force required to perform simple daily tasks. The aeroponic system reduces the amount of labor needed to operate the system, thus reducing the labor staff.

Hank and I personally use the cannabis plant and would promote our clean, sustainable, and earth friendly product over any other system on the market.

• Please explain to our audience what the Blackbox aeroponics growing method is, what makes it unique, and how it is a benefit to the overall operation.

Our Blackbox system has really evolved over the past 12 years of tinkering with and improving the design. We’ve been honing the system to provide the most precise and beneficial mix of nutrients, air, and water simultaneously. In general, aeroponics technologies have come a long way, and we have customized what’s available to fit our own concepts.

The Blackbox system allows the plants to grow in air, using zero media. This in turn results in sustainable, efficient, and economic practices by eliminating a raw material. Also, by not using a media, pesticides are also eliminated due to the sterile growing environment. The system is a closed-loop system, meaning the water used is recaptured, reconditioned and sent back to the plants. BlackBox is modular for any scaled project, from acres of plants down to homegrown setups.

• What is a sun chamber, and how does it differ from a greenhouse? What are the benefits?

The Ceres SunChamber is more than a greenhouse. It is a holistic system – a completely sealed grow environment characterized by its light and warmth harvesting and climate control capabilities. It is an all inclusive design of the perfect growing environment for all components needed A-Z.

The combination of a glass ceiling that allows high light-transmittance with insulated metal walls ensure energy efficiency and maximum climate control over the growing environment. Sealed cannabis greenhouses also increase biosecurity and do not allow odors to escape or leak out. SunChambers are high-performance sealed greenhouse systems that maintain the Vapor Pressure Deficit (VPD) required to cultivate superior cannabis plants.

Cooling and heating a cannabis greenhouse can often be expensive. Blackbox leverages the technology of the Ceres EcoLoop geothermal HVAC system, a renewable energy source that utilizes the earth’s steady temperature to create precise, desired climates in each of the SunChambers.

The SunChambers also allow smaller batches of up to 500 plants at a time. Biosecurity is maintained by isolation of each SunChamber if any problems were to happen in the facility. Large open greenhouses are susceptible to infestation, wiping out the entire crop if left un-checked.

• How does your grow technology support sustainability?

Ceres SunChambers are 7 times more efficient than an indoor cultivation operation, and 3.5 times more efficient than standard greenhouses. So energy use is greatly decreased. Then the Blackbox aeroponics systems adds another layer of sustainability. Zero media waste, zero pesticides, ultra-low precise water usage… it all adds up to the most sustainable, lowest impact, most efficient design we can implement.

• Why did you choose to begin your multi-state strategy in Michigan, and what is the status of your license application there?

Michigan is the home of both of the Blackbox founders. Hank and I grew up in Dunham Hills in Hartland, Michigan. We have deep-rooted family and business ties in the construction trades throughout the region. We love it here, so why wouldn’t we start our business here?

But Michigan has a number of other things going for it as well. It is one of the largest and fastest growing legal cannabis markets in the country. The regulatory environment is very friendly to a business like ours. The Michigan Regulatory Agency (MRA) does a great job shepherding the industry in the state. And centrally-located Michigan would be an ideal spot for a national distribution operation should the US government make cannabis federally legal.

Click here to learn more about investing in Hero Technologies

Blackbox and Hero Technologies have completed and been approved by MRA through step 1 (of a 2-step process) for both recreational and medial cannabis operations. We have also completed application and been approved by the local Pulaski Township Board for 3 Class-C Medical cannabis cultivation licenses.

• Why is Pulaski a good location for your operations?

Pulaski is located in south/central Michigan and can service the entire state of Michigan with ease. Also, Pulaski Township has placed a cap on any new medical cannabis licenses which limits local competition. Add in the ideal location for a national distribution center and we really like where we are.

• Is there anything else you would like to share with potential investors?

Stick with us if you know our story, and join in if you are finding out about us for the first time! We are very excited to get the project off the ground and realize the fruits of our 12 years of research and development.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

The state of Michigan is one of the hottest legal cannabis markets in the United States. According to Andrew Brisbo, Executive Director of Michigan’s Marijuana Regulatory Agency, the state recently passed the $3 billion dollar mark in total sales since October 2018. For 2021 alone, total sales topped $1.79 billion. The industry has been growing steadily in Michigan since its inception. In the graph below, the bottom orange line represents medical sales, the middle gray line is recreational sales, and the top yellow line is the total sales.

Source: Michigan Marijuana Regulatory Agency

Michigan’s market is ranked the 7th largest in the US and is knocking on the doors of more established and larger markets like Illinois, Oregon, and Massachusetts. Considering the growth there, and the generally friendly regulatory environment, Michigan would be a logical choice as a place to start for a company with ambitions to become a successful multi-state operator (MSO).

Click here to learn more about investing in Michigan Cannabis

Hero Technologies Inc. (OTC: HENC) is one company that has taken notice and is acting on it. The company has completed the prequalification process for licensing in Michigan and is contemplating the construction of a large cultivation facility in the state. Let’s take a look at what Hero Technologies is up to and where the business might be headed.

Innovative Cultivation System

Hero Technologies owns a majority, controlling interest in  BlackBox Systems and is applying for licenses through this subsidiary. BlackBox, and its founder and CEO Marc Kasabasic, have been operating in Michigan as medical caregivers. With Hero’s backing, the company is looking to greatly expand operations in the state with new adult-use and medicinal licenses. The key to the company’s approach is a patent-pending aeroponic cultivation system. In the video below, Kasabasic discusses the innovative system and its capabilities.

[embedded content]

Potential advantages of the system include extensive automation, elimination of soils and other substrates, no pesticides, decrease in parasite risk, and high efficiency. The proposed cultivation facility employs the use of sun chambers, rather than a typical greenhouse design. Sun chambers are built like normal buildings, with insulated walls, but have glass roofs to allow for sunlight. The design is sturdier in the face of severe weather than a full greenhouse while taking advantage of both the heat retention of traditional structures and the reduced lighting requirements of greenhouses.

The 120 acre site in Pulaski, MI has been chosen and much work has been done on the design and permitting processes with the various local and state regulators. Hero Technologies plans to use the facility as the cornerstone of its vertically integrated business model. The company’s strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multi-state operator.

Hero Technologies is in the process of upgrading its listing with OTC Markets to the OTCQB level. OTCQB companies have heightened certification and reporting requirements that ensure a high level of transparency for potential investors and stakeholders.

Investors are encouraged to keep an eye on Hero Technologies’ developments over the coming quarters. Hero represents an early-stage opportunity in the flourishing Michigan legal cannabis market, and the company hopes to expand well beyond those borders in the coming years. Stay tuned.

Click here to learn more about investing in Michigan Cannabis

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

Researchers believe that psychedelics may revolutionize mental health treatments, but FDA-approved psychedelics remain out of reach—with one exception. Unlike psilocybin or MDMA, ketamine is FDA-approved for anesthesia during medical procedures, opening the door to off-label use as a treatment for depression and other mental illnesses.

With the FDA’s approval of Spravato and a growing body of research supporting ketamine, patients are increasingly turning toward these clinics to solve their unmet medical needs.

Ketamine clinics charge between $450 and $500 per treatment, with each patient needing approximately six treatments. In aggregate, some analysts estimate that the market is already worth north of $16 billion per year, with rapid growth possible over the coming years. 

Let’s take a look at three ways that you can invest in ketamine clinics.

Revitalist Lifestyle

Revitalist Lifestyle & Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE:4DO) is one of the most exciting pure-plays in the ketamine clinic space. Since opening its first clinic in 2018, the company has built a network of eight clinics across four states, with two additional clinics to open by the end of the year in Bethesda, MD and a second Knoxville, TN location. In addition, January 1, 2022 will see two newly acquired clinics in Richmond, VA. and Jacksonville, FL, with more than 60,650 sq. ft. of space and clinical capacity for more than 120 treatment rooms. All of Revitalist’s treatments are provided by certified registered nurse anesthetists with ketamine experience and mental health or psychiatric practitioners licensed to administer the drug.

Last quarter, the company reported $1.55 million in revenue and $1.17 million in gross income for the ten months leading up to October 31, 2021. Management believes that its existing 120 treatment rooms could generate upwards of $60 million in annual revenue, while it plans to open 50 clinics in 2022 before reaching 150 clinics by 2025.

The company also plans to launch a telemedicine platform over the coming months. These efforts could significantly expand its addressable market across geographies. And with its 60% acquisition of Revitaland Meta Tech Inc., the platform could expand to include virtual clinics in the metaverse—a rapidly growing innovation spearheaded by Facebook.

Click here to learn more about investing in Revitalist

Field Trip Health

Field Trip Health Ltd. (NASDAQ: FTRP) is the largest ketamine clinic operator with a $150 million market capitalization. In addition to psychedelic drug development, the company operates six clinics and plans to expand to 75 locations by 2024. These clinics provide psychedelic-assisted psychotherapy with the help of ketamine.

The company also provides a digital platform to support patients through their therapeutic journey. The platform offers mood monitoring, mindfulness tools, information, and guided meditations, along with video calls and asynchronous text communication. The goal is to help collect data and improve patient outcomes.

Novamind

Novamind Inc. (CSE: NM) (OTC: NVMDF) operates a network of six ketamine clinics and clinical research sites in Utah. In 2022, the company plans to add new clinics in Utah and expand into Arizona for a total of ten clinics. These will include a center for immersive psychedelic experiences in Park City, Utah, a world-class travel and wellness destination.

In addition to ketamine therapies, the company operates a full-service psychedelic contract research organization (CRO) with three clinical research sites and a DEA Schedule 1 license for psilocybin research. These facilities could help it play a role in the study and eventual approval of psilocybin, MDMA, and other psychedelic therapies.

Looking Ahead

Ketamine clinics are quickly becoming a multi-billion dollar business driven by rapidly growing demand. Investors interested in the space have several options, including pure-plays like Revitalist Lifestyle & Wellness Ltd. (CSE: CALM) (OTC: RVLWF). 

For more information, visit the company’s website or download their investor presentation.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.